An efficacy and safety study of Telaprevir in patients with genotype 1 Hepatitis C infection after liver transplantation

Update Il y a 4 ans
Reference: EUCTR2011-004724-35

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

to determine the efficacy of telaprevir administered as 750 mg every 8 hours (q8h) in combination with pegylated interferon (Peg-IFN)-alfa-2a and ribavirin (RBV) in genotype 1 chronic HCV infected liver transplant patients as measured by sustained virologic response (SVR12planned). SVR12planned is defined as having HCV ribonucleic <25 IU/mL acid (RNA) level 12 weeks after the last planned dose of study medication.


Inclusion criteria

  • Chronic Hepatitis C Infection